Project Grant R21CA301146
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$218K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $1,088,500.00 to the University of California, Santa Barbara (UCSB) to develop enhanced cellular immunotherapies like chimeric antigen receptor macrophages (CAR-M) for treating prevalent solid tumors as well as hard-to-treat cancers such as ovarian, pancreatic, and glioblastoma. The research aims to overcome key limitations of existing cellular immunotherapies by...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $645,873 to The University of Texas MD Anderson Cancer Center to develop an innovative in vivo approach for generating chimeric antigen receptor (CAR) macrophages targeting the epidermal growth factor receptor variant III (EGFRvIII) for treating glioblastoma, the most common and lethal form of brain cancer in adults. The key products and services to be delivered include:
Evaluating...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will fund research conducted by the University of California, San Diego (UCSD) to develop a novel gene therapy approach to engineer immune cells to effectively target and kill ovarian cancer cells. The $222,998 award, granted on March 10, 2025, aims to utilize virus-like particles to deliver chimeric antigen receptors (CARs) that will enable T cells, NK cells, and...
This $236,776 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) program supports the development of a modular, logic-gated "split CAR" format for chimeric antigen receptor (CAR) T cell cancer therapies. The project aims to engineer CAR T cells that can selectively activate and target solid tumor cells by responding to both tumor...
The U.S. National Cancer Institute awarded a $544,866 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Francisco (UCSF) to develop a novel bispecific T cell engager that targets the tumor-specific antigen ALPPL2. The funding will support research aimed at optimizing the target specificity, CD3 arm engineering, and molecular architecture of the bispecific molecule to maximize its therapeutic potential and enable clinical translation for the treatment...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health (CFDA 93.286) federal grant program is funding research to develop a "three-cell (T-NK-macrophage) synthetic immunotherapy system" for cancer treatment. The $207,900 award to The Leland Stanford Junior University aims to screen libraries of chimeric antigen receptors (CARs) and synthetic cytokine...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a two-pronged approach to target triple-negative breast cancer (TNBC). The $403,686 award, effective June 1, 2024 through May 31, 2026, will enable researchers at Rutgers, The State University of New Jersey to:
Explore the use of a targeted hybrid vector called AAVP to deliver human tumor necrosis factor (TNF) to both TNBC tumor cells and associated...
This $1,271,780 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop small molecule adaptors for reprogramming universal chimeric antigen receptor (CAR) T cells. The primary objectives are to: 1) create small molecule adaptors to target universal CAR T cells to multiple antigens, including tumor cells and immunosuppressive cells; 2) enhance CAR targeting specificity using chemical switches...
The National Science Foundation awarded a $458,569 Project Grant to the University of Southern California under the Engineering federal grant program (CFDA 47.041) to support research developing next-generation chimeric antigen receptor T-cells for cancer immunotherapy using phosphoproteomics. Over a five-year period ending March 2027, the University of Southern California will identify signaling pathways that enhance tumor killing in CAR-T cells and define CAR signaling pathways enabling...
The National Cancer Institute (NCI) has awarded a $587,108 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant aims to enhance the efficacy and durability of chimeric antigen receptor (CAR) T cell immunotherapy by modulating interferon type I (IFN1) signaling in non-activated T cells.
The key goals of this 5-year research project are to: 1)...